Calypte gets HIV test order in Burkina Faso:
This article was originally published in Clinica
Executive Summary
Alameda, California-based Calypte Biomedical has received its first West African order for its urine-based HIV-1 antibody test, for use in Burkina Faso, which has a population of some 12 million people, with an adult HIV rate of 6.5%. "We would expect that as word of favourable experience with Calypte's urine HIV test spreads, this initial order should drive future sales, not only in Burkina, but elsewhere in the region," said Tony Cataldo, chairman. The company is using a Burkinabe distributor and hopes to expand into Benin, Togo, Ivory Coast, Mali and Niger over the next year.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.